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General Methods. Reagents and solvents were purchased from commercial sources 
and used without further purification. Optical rotations were measured at 20 ± 2 ºC in 1-
cm or 1-dm tubes. 1H (and 13C NMR) spectra were recorded at 500 (125.7), 400 (100.6) 
and 300 (75.5) MHz. 2D COSY and HMQC experiments were carried out to assist on 
NMR assignments. Thin-layer chromatography (TLC) was carried out on aluminium 
sheets, silica gel 30F-245, with visualization by UV light and by charring with 10% 
H2SO4 or 0.2% ninhydrine in EtOH. Column chromatography was carried out on 
normal-phase Silica Gel (E. Merk, 230-400 mesh). MALDI-TOF mass spectra were 
acquired on a GSG System spectrometer operating in the positive-ion mode with an 
accelerating voltage of 28 keV. Samples were dissolved in water at mM concentration 
and mixed with a standard solution of 2,5-dihydroxybenzoic acid (DHB; 10 mg mL-1 in 
10% aq EtOH, 2 μL) in 1:1 v/v relative proportions; 1 μL of the mixture was loaded 
onto the target plate, then allowed to air-dry at room temperature. Electrospray mass 
spectra were obtained for samples dissolved in MeCN, MeOH or H2O-MeOH at mM 
concentrations. Elemental analyses were performed by the Instituto de Investigaciones 
Químicas, Sevilla, Spain. 
Preparation of Complexes from Amphiphilic βCD Click Clusters and 
Plasmid pEGFP-N3.  The plasmid pEGFP-N3, used  for the preparation of the  DNA 
complexes and for transfection assay is a plasmid of 4729 bp (base pairs). The 
quantities of amphiphilic βCD click clusters used were calculated according to the 
desired DNA concentration of 0.05 mg/mL (150 μM phosphate), the N/P ratio, the 
molar weight and the number of positive charges in the selected CD derivative. 
Experiments were performed for N/P 5, 10, 20 and 50. DNA was diluted in Milli-Q 
water to a final concentration of 150 μM phosphate, then the desired amount of CD 
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derivative was added from a 20 mg/mL stock solution (1:2 Me2SO-water). The solution 
was previously diluted so that the desired N/P ratio was reached by mixing with an 
equal volume of the plasmid solution. In this way, the Me2SO proportion was identical 
in all experiments (16.7% v/v). The preparation was vortexed for a few seconds and 
incubated for 30 minutes.  
Vesicle Preparation: Vesicles of CDs were prepared by sonication. Typically, 
the amphiphilic βCD in HPLC-grade MeOH (50 μM) was dried by using a warm air 
stream to yield a thin film in a glass vial. The residual solvent was removed under high 
vacuum for 1-2 h. Milli-Q water (4 mL) was added and the sample solution was kept for 
30 min at 50 ºC. The resulting suspension was sonicated for 30 min at rt to give small 
vesicles.  
Particle Size and ζ Potential Measurements. The hydrodynamic diameters of 
the vesicles formed from the amphiphilic βCD click clusters as well as that of the 
corresponding CDplexes were measured by Dynamic Light Scattering at 633 nm on a 
Zetamaster S Dynamic Light Scattering instrument (Malvern Instruments) at 25 ºC and 
at a detection angle of 90º. All the measurements were performed in triplicate. 
Statistical analysis of the particle size was performed using a student’s test (with two-
sample unequal variance and two distribution tails). The ζ potential measurements were 
also performed using the same instrument at a detection angle of 90º in triplicate. 
Results are collected in Table S1. 
Table S1. Hydrodynamic Diameter and ζ Potential for Micelles and CDplexes 
from Ampihphilic βCD Click Clucters. 
Compound or 
CDplex 
Hydrodynamic 
Diameter (nm) 
Polydispersity 
Index (PI) 
ζ Potential (mV) 
11 125 ± 10 0.15 ± 0.03 17 ± 3  
12 81± 21 0.25 ± 0.09 52 ± 4  
13 210 ± 15 0.30 ± 0.02 59 ± 4 
13:pDNA 103 ± 5 0.17 ± 0.08 48 ± 2  
14 421 ± 12 0.09 ± 0.03 44 ± 2 
14:pDNA 111 ± 10 0.25 ± 0.02 44 ± 6 
15 482 ± 30 0.32± 0.228 57 ± 9 
15:pDNA 155 ± 12 0.31 ± 0.02 33 ± 6 
21 216 ± 15 0.33 ± 0.02 49 ± 4 
21:pDNA 99 ± 6 0.23 ± 0.04 44 ± 3 
22 336 ± 15 0.19 ± 0.09 70 ± 3 
22:pDNA 120 ± 5 0.26 ± 0.01 50 ± 4 
 
Cell Culture and DNA Transfection Assays. Wild type Chinese Hamster 
Ovary (CHO-k1; ATCC no. CCL-61) cells were grown in Dulbecco´s Modified Eagle´s 
 3
medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 2 mM Glutamine 
plus, 100 U/mL penicillin, and 0.1 µg/mL streptomycin. Prior to transfection, cells were 
seeded in 24 well plates and incubated for 24 h to reach a cell confluency of 80-90%. 
For transfection experiments, pEGFP-N3 plasmid (1 μg) was mixed with the 
corresponding CD derivative at N/P ratios of 5, 10, 20 and 50 at room temperature for 
20 minutes in a final volume of 20 μl. The mixture was diluted to 0.5 ml with DMEM 
without serum or with 10% serum and added to each well. Untransfected cells and 
naked pEGFP-N3 were used as negative controls. As a positive control, a transfection 
experiment was performed using 2 μL of LipofectamineTM 2000 (Invitrogen) and 1.0 μg 
of DNA, according to the manufacturer’s instructions.  Cells were incubated with the 
DNA-amphiphilic βCD mixtures for 5 h, then the transfection media was removed and 
cells were further grown in DMEM media plus 10% FBS for an additional period of 48 
h. For results on transfection see Table 1 in the manuscript.  
Fluorescence and Protein Assays. Transfected cells were washed three times 
with PBS and 600 μL of 0.5 % triton X-100 in PBS was added. The plates were shaken 
for 10 min at room temperature, the lysate was recovered and the fluorescence was 
quantified in a Shimadzu RF-5301PC fluorimeter with excitation of 460 nm (5 nm) and 
510 nm (10 nm) emission wavelengths. Protein concentration was measured using the 
Bio-Rad Protein Assay (Hercules, CA, USA). 
Statistical analysis. Results are expressed as mean ± SEM for the number of 
experiment indicated. The statistical significance of variations was evaluated using one-
way Analysis of Variance (ANOVA). When significant effect was found, post hoc 
comparisons of the means were done using the t adjusted Tukey’s test. A p value < 0.05 
was considered significant. According to this criterion, differences between the data for 
LipofectamineTM 2000 and compounds 14 and 22 in Figure 2b were found not 
significant. Similarly, differences between the transfection data for LipofectamineTM 
2000 and compound 14-based CDplexes (see Figure 2c in the manuscript) were not 
significant. 
Gel Electrophoresis Shift Assay. The DNA-amphiphilic βCD click cluster 
binding capability was analyzed by gel electrophoresis. The stock solutions of βCD 
derivatives were prepared in a 1:2 Me2SO-water, while DNA was dissolved in Milli-Q 
water. pEGFP-N3 DNA (10 μL at 0.1 μg/μL) was mixed with an equal volume of βCD 
derivative using  N/P ratios 0 to 100 and incubated for 30 min at room temperature 
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before the addition of loading buffer (2 μL). An aliquot (5 μL) of each sample was 
subjected to agarose gel electrophoresis (0.8% w/v) in TAE buffer (40 mM Tris-acetate, 
1 mM EDTA). Electrophoresis was carried out at 7 V/cm and gels were stained after 
electrophoresis with ethidium bromide. Quantification of the band intensity was 
performed with the NIH Image Software.1 A value of 1 has been assigned to the 
intensity of the band corresponding to the naked DNA. 
DNase Protection Assays. pEGFP-N3 DNA (10 μL at 0.1 μg/μL) was mixed 
with an equal volume of stock solution of βCD derivative using N/P = 5 and incubated 
for 30 min at room temperature. To the mixture, 15 μL of a solution of DNase I (0.1 
mg/mL in Tris HCl 50 mM pH 8, 2000 U/mg) were added and incubated for 1 h at 37 
ºC. After the digestion, 20 μL of a 10 % SDS solution was added and the samples were 
incubated for 15 min at 65 ºC. Finally, an aliquot (20 μL) of each sample was subjected 
to agarose gel electrophoresis (0.8% w/v) in TAE buffer. 
Materials. Heptakis(6-azido-6-deoxy)cyclomaltoheptaose (1),2  N-(tert-butoxy-
carbonylamino)propargylamine (4),3 bis[2-(tert-butoxycarbonylamino)ethyl]-amine,4 
and heptakis[6-(2-aminoethylthio)-6-deoxy-2,3-di-O-hexanoyl]-cyclomaltoheptaose 
heptahydrochloride5 were prepared according to literature procedures. pEGFP-N3 
plasmid (Genbank Accession #: U57609) was obtained from Clontech Laboratories 
(Palo Alto, CA). This 4729 bp plasmid encodes for a red-shifted variant of wild-type 
GFP. Plasmid was purified from transfected bacteria using standard methods.6 DNA 
concentration was measured using a fluorimetric method using the Hoechst 33258 dye.7 
Heptakis(6-azido-6-deoxy-2,3-di-O-hexanoyl)cyclomaltoheptaose (2): To a 
solution of heptakis(6-azido-6-deoxy)cyclomaltoheptaose (1, 0.2 g, 0.15 mmol) in dry 
DMF (20 mL) under Ar at 0 ºC, DMAP (783 mg, 6.4 mmol, 3 eq.) was added. Hexanoic 
anhydride (2.0 ml, 8.5 mmol, 4 eq) was dropwise added, the reaction mixture was 
stirred at rt for 16 h, then MeOH (20 mL) was added. After 1 h, the solution was poured 
into ice-water (50 mL) and extracted with CH2Cl2 (4 x 50 mL). The organic phase was 
washed with 2 N H2SO4 (2 x 50 mL), water and saturated aqueous NaHCO3 (4 x 50 
mL), dried (Na2SO4), concentrated and purified by column chromatography (1:15 → 
1:9 EtOAc-petroleum ether). Yield.: 286 mg (71%); Rf 0.42 (1:9 EtOAc-petroleum 
ether); [α]D = +115.0 (c 1.0, CH2Cl2);  IR: υmax 2117 cm-1; 1H NMR (500 MHz, CDCl3): 
δ5.30 (t, 7 H, J2,3 = J3,4 = 9.2 Hz, H-3), 5.06 (d, 7 H, J1,2 = 3.8 Hz, H-1), 4.80 (dd, 7 H, 
H-2), 4.00 (ddd, 7 H, J4,5 = 9.2 Hz, J5,6b = 4.9 Hz, J5,6a = 2.7 Hz,  H-5), 3.73 (t, 7 H, H-
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4), 3.71 (dd, 7 H, J6a,6b = 13.6 Hz, H-6a), 3.63 (dd, 7 H, H-6b), 2.40-2.16 (m, 28 H, 
CH2CO), 1.59 (m, 28 H, CH2CH2CO), 1.30 (m, 56 H, CH2CH3, CH2CH2CH3), 0.91, 
0.89 (2 t, 42 H, 3JH,H = 7.3 Hz, CH3); 13C NMR (125.7 MHz, CDCl3): δ173.2, 171.7 
(CO), 96.4 (C-1), 76.7 (C-4), 70.8 (C-5), 70.1 (C-2, C-3), 51.6 (C-6), 34.0, 33.8 
(CH2CO), 31.4, 31.2 (CH2CH2CH3), 24.6, 24.3 (CH2CH2CO), 22.3 (CH2CH3), 13.8 
(CH3). ESIMS: m/z 2706.3 [M + Na]+. Anal. Calcd for C126H203N21O42: C 56.38, H 
7.62, N 10.96. Found: C 56.33, H 7.23, N 10.93. 
Heptakis(6-azido-6-deoxy-2,3-di-O-myristoyl)cyclomaltoheptaose (3). To a 
solution of heptakis(6-azido-6-deoxy)cyclomaltoheptaose (1, 100 mg, 76.3 μmol) in dry 
DMF (7 mL) under Ar at 0 ºC, DMAP (392 mg, 3.2 mmol, 3 eq) was added. Myristic 
anhydride (1.87 g, 4.3 mmol, 4 eq) was dropwise added, the reaction mixture was 
stirred at rt for 16 h, then MeOH-CH2Cl2 (95:5, 25 mL) was added. After 1 h, the 
solution was decanted and the resulting solid was dried. Yield.: 315 mg (97%); Rf  0.40 
(1:8 EtOAc-petroleum ether); [α]D = +66.1 (c 1.0, CH2Cl2); 1H NMR (500 MHz, 
CDCl3): δ 5.28 (t, 7 H, J2,3 = J3,4 = 9.3 Hz, H-3), 5.02 (d, 7 H, J1,2 = 3.6 Hz, H-1), 4.77 
(dd, 7 H, H-2), 3.98 (m, 7 H, H-5), 3.71 (t, 7 H, J4,5 = 9.5 Hz, H-4), 3.68 (m, 7 H, H-6a), 
3.60 (dd, 7 H, J6a,6b = 13.5 Hz, J5,6b = 4.5 Hz, H-6b), 2.32, 2.21 (m, 28 H, CH2CO), 1.53 
(m, 28 H, CH2CH2CO), 1.25 (m, 280 H, CH2), 0.86 (t, 42 H, 3JH,H = 7.1 Hz, CH3); 13C 
NMR (125.7 MHz, CDCl3): δ 173.2, 171.8 (CO), 96.4 (C-1), 76.7 (C-4), 70.8 (C-5), 
70.2 (C-2), 70.1 (C-3), 51.6 (C-6), 34.1, 33.9 (CH2CO), 32.0 (CH2CH2CH3), 29.9-29.2 
(CH2), 24.9, 24.8 (CH2CH2CO), 22.7 (CH2CH3), 14.0 (CH3). MALDI-TOFMS: m/z 
4523.7 [M + H]+. Anal. Calcd for C238H427N27O42: C 67.18, H 10.11, N 6.91. Found: C 
66.82, H 9.84, N 6.66.  
3-Bis[2-(tert-butoxycarbonylamino)ethyl]aminopropine (5): To a solution of 
bis[2-(tert-butoxycarbonylamino)ethyl]amine (872 mg, 2.86 mmol) and Et3N (1.2 mL, 
8.6 mmol, 3.0 eq) in CH3CN (15 mL), propargyl bromide was added (0.90 mL, 8.6 
mmol, 3.0 eq) and the mixture was stirred for 2 days. The solvent was eliminated under 
vacuum and the residue was dissolved in CH2Cl2 (100 mL), washed with water (3 x 30 
mL), dried (MgSO4), and concentrated. The resulting residue was purified by column 
chromatography (30:1 CH2Cl2-MeOH). Yield: 567 mg (58%); Rf = 0.22 (50:1 CH2Cl2-
MeOH); 1H NMR (300 MHz, CDCl3): δ 4.93 (bs, 2 H, NH), 3.42 (d, 2 H, 4JH,H = 2.4 
Hz, CH2C≡CH), 3.20 (q, 4 H, 3JH,H = 5.7 Hz, CH2NHBoc), 2.64 (t, 4 H, 
CH2CH2NHBoc), 2.20 (t, 1 H, C≡CH), 1.45 (s, 18 H, CMe3);  13C NMR (75.5 MHz, 
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CDCl3): δ 156.0 (CO), 79.2 (Cq), 77.9 (C≡CH), 73.4 (C≡CH), 52.8 (CH2CH2NHBoc), 
41.8 (HC≡CCH2), 38.0 (CH2NHBoc), 28.4 (CMe3). ESIMS: m/z 364.2 [M + Na]+, 342.2 
[M + H]+. Anal. Calcd. for C17H31N3O4: C 59.80, H 9.15, N 12.31. Found: C 59.87, H 
9.03, N 12.18.  
Heptakis[6-(4-tert-butoxycarbonylaminomethyl-1H-1,2,3-triazol-1-yl)-6-
deoxy] cyclomaltoheptaose (6): To a solution of heptakis (6-azido-6-deoxy)-
cyclomaltoheptaose (1, 200 mg, 0.15 mmol) and N-(tert-butoxycarbonylamino)-
propargylamine (4, 180 mg, 1.15 mmol, 1.1 eq) in DMF (6 mL), CuI (70 mg, 0.37 
mmol, 0.3 eq) and water (6 mL) were added. The reaction mixture was heated for 2 h at 
100 ºC. The solvent was eliminated under reduced pressure and the residue was purified 
by column chromatography (10:1:1 → 10:2:1 MeCN-H2O-NH4OH) to give 6. Yield: 
181 mg (50%); Rf 0.38 (10:2:1 MeCN-H2O-NH4OH); [α]D = +17.0 (c 1.0, MeOH); 1H 
NMR (500 MHz, CD3OD, 323 K): δ 7.80 (s, 7 H, =CH), 5.18 (s, 7 H, H-1), 4.61 (m, 7 
H, H-6a), 4.40 (bd, 7 H, J6a,6b = 8.6 Hz, H-6b), 4.20 (m, 21 H, CH2NHBoc, H-5),  3.89 
(t, 7 H, J2,3 = J3,4 = 9.3 Hz,  H-3), 3.48 (dd, 7 H, J1,2 = 3.1 Hz, H-2), 3.35 (t, 7 H, J4,5 = 
8.7 Hz, H-4), 1.42 (s, 63 H, CMe3); 13C NMR (125.7 MHz, CD3OD, 323 K): δ 158.0 
(CO), 147.1 (C-4 triazole), 126.0 (C-5 triazole), 103.6 (C-1), 84.5 (C-4), 80.5 (Cq), 74.3 
(C-3), 73.8 (C-2), 71.7 (C-5), 51.4 (C-6), 37.0 (CH2NHBoc), 29.0 (CMe3); ESIMS: m/z 
1221 [M + 2 Na]2+. Anal. Calcd. for  C98H154N28O42: C 49.12, H 6.48, N 16.37. Found: 
C 49.08,  H 6.33, N 16.24. 
Heptakis[6-(4-(2,2-bis(tert-butoxycarbonylamino)ethylaminomethyl)-1H-
1,2,3-triazol-1-yl)-6-deoxy]cyclomaltoheptaose (7). A solution of heptakis[6-azido-6-
deoxy]cyclomaltoheptaose (1, 107 mg, 82 μmol), 5 (216 mg, 0.63 mmol, 1.1 eq)  and 
CuI (33 mg, 0.17 mmol, 0.3 eq. ) in DMF:H2O (1:1, 6 mL) was heated for 2 h at 100 ºC. 
The solvent was evaporated under reduced pressure and the residue was purified by 
column chromatography (20:1:1 → 10:1:1 MeCN-H2O-NH4OH). Yield: 204 mg (67%); 
Rf 0.24 (10:2:1 MeCN-H2O-NH4OH); [α]D = +12.7 (c 1.0, MeOH); 1H NMR (500 
MHz, CD3OD, 323 K): δ 7.89 (s, 7 H, =CH), 5.17 (d, 7 H, J1,2 = 3.5 Hz, H-1), 4.55 (m, 
14 H, H-6a, H-6b), 4.30 (m, 7 H, H-5), 3.92 (t, 7 H, J2,3 = J3,4 = 9.3 Hz, H-3), 3.77, 3.68 
(2 d, 14 H, 2JH,H = 14.5 Hz, CH2N), 3.44 (dd, 7 H, H-2), 3.31 (t, 7 H, J4,5 = 9.1 Hz, H-4), 
3.18-3.11 (m, 28 H, CH2NHBoc), 2.64-2.56 (m, 28 H, CH2CH2NHBoc), 1.46 (s, 126 H, 
CMe3); 13C NMR (125.7 MHz, CD3OD, 313 K): δ 158.2 (CO), 145.5 (C-4 triazole), 
127.1 (C-5 triazole), 103.8 (C-1), 84.6 (C-4), 80.0 (Cq), 74.4 (C-3), 74.0 (C-2), 71.6 (C-
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5), 54.5 (CH2CH2NHBoc), 51.5 (C-6), 49.0 (CH2N), 39.5 (CH2NHBoc), 29.0 (CMe3); 
ESIMS: m/z  1849.3 [M + Na + H]2+, 1240 [M+ 2H + Na]3+. Anal. Calcd for 
C161H280N42O56: C 52.26, H 7.63, N 15.90. Found C 51.90, H 7.33, N 15.54 . 
Heptakis[6-(4-tert-butoxycarbonylaminomethyl-1H-1,2,3-triazol-1-yl)-6-
deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (8): To a solution of 2 (765 mg, 0.28 
mmol) and N-tert-butoxycarbonylpropargylamine (4, 405 mg, 2.59 mmol, 1.3 eq) in 
acetone (10 mL), CuI·(EtO)3P (71 mg, 200 μmol, 0.3 eq) and DIPEA (0.34 mL, 0.29 
mmol, 1 eq) were added and the reaction mixture was refluxed for 3 h. The solvent was 
evaporated under reduced pressure and the resulting residue was purified by column 
chromatography (50:1 → 20:1 CH2Cl2-MeOH). Yield: 871 mg (81%). Rf 0.47 (15:1 
CH2Cl2-MeOH); [α]D = +24.7 (c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3, 313 K): δ 
7.62 (s, 7 H, =CH), 5.45 (s, 7 H, H-1), 5.40 (s, 7 H, NHBoc),  5.38 (t, 7 H, J2,3 = J3,4 = 
8.0 Hz, H-3), 4.86 (bd, 7 H, J6a,6b = 13.7 Hz, H-6a), 4.75 (dd, 7 H, J1,2 = 2.1 Hz, H-2), 
4.57 (bs, 7 H, H-6b), 4.48 (bs, 7 H, H-5), 4.29 (dd, 7 H, 2JH,H = 15.2 Hz, JCH,NH = 5.4 
Hz, CHaNHBoc), 4.18 (dd, 7 H, JCH,NH = 3.0 Hz, CHbNHBoc), 3.55 (t, 7 H, J4,5 = 8.0 
Hz, H-4), 2.36-2.13 (m, 28 H, CH2CO), 1.57 (m, 28 H, CH2CH2CO), 1.40 (s, 63 H, 
CMe3), 1.30 (m, 56 H, CH2CH3, CH2CH2CH3), 0.90 (t, 42 H, 3JH,H = 7.0 Hz, CH3). 13C 
NMR (125.7 MHz, CDCl3, 313 K): δ 172.9, 171.6 ( CO ester), 155.8 (CO carbamate), 
145.2 (C-4 triazole), 124.6 (C-5 triazole), 96.4 (C-1), 79.5 (C-4, Cq), 70.1 (C-3), 69.8 
(C-5), 69.6 (C-2), 50.2 (C-6), 36.1 (CH2NHBoc), 33.8 (CH2CO), 31.4, 31.2 
(CH2CH2CH3), 28.3 (CMe3), 24.3 (CH2CH2CO), 22.3 (CH2CH3), 13.8 (CH3). ESIMS: 
m/z 1908.1 [M + 2 Na]2+. Anal. Calcd for C182H294N28O56: C 57.98, H 7.86, N 10.40. 
Found: C 58.04, H 7.76, N 10.32. 
Heptakis[6-(4-(2,2-bis-tert-butoxycarbonylamino)ethylaminomethyl)-1H-
1,2,3-triazol-1-yl)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (9). To a solution 
of 2 (156 mg, 58 μmol) and 5 (182 mg, 0.53 mmol, 1.3 eq) in acetone (10 mL), 
CuI·(EtO)3P (15 mg, 41 μmol, 0.1 eq) was added and the reaction mixture was refluxed 
for 3 h. The solvent was evaporated under vacuum and the residue was purified by 
column chromatography (30:1 → 9:1 CH2Cl2-MeOH). Yield: 256 mg (87 %); Rf  = 0.61 
(9:1 CH2Cl2:MeOH); [α]D = +25.9 (c 1.0, CH2Cl2); 1H NMR (400 MHz, CDCl3, 323 
K): δ 7.73 (s, 7 H, =CH), 5.44 (d, 7 H, J1,2 = 3.2 Hz, H-1), 5.36 (t, 7 H, J2,3 = J3,4 = 8.7 
Hz, H-3), 5.21 (bs, 14 H, NHBoc) 4.90 (bd, 7 H, J6a,6b = 13.6 Hz, H-6a), 4.75 (dd, 14 H, 
H-2, H-6b), 4.51 (m, 7 H, H-5), 3.78, 3.74 (2 d, 14 H, 2JH,H = 15.6 Hz, CH2N), 3.53 (t, 7 
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H, J4,5 = 8.5 Hz, H-4), 3.16 (q, 28 H, 3JH,H = 5.6 Hz, CH2NHBoc), 2.56 (t, 28 H, 
CH2CH2NHBoc), 2.45-2.13 (m, 28 H, CH2CO), 1.60 (m, 28 H, CH2CH2CO), 1.44 (bs, 
126 H, CMe3), 1.30-1.20 (m, 56 H, CH2CH3, CH2CH2CH3), 0.94, 0.93 (2 t, 42 H, 3JH,H 
= 7.2 Hz, 3JH,H = 6.8 Hz, CH3); 13C NMR (100.6 MHz, CDCl3, 323 K): δ 172.7, 171.5 
( CO ester), 156.0 (CO carbamate), 143.6 (C-4 triazole), 125.4 (C-5 triazole), 96.5 (C-1), 
78.8 (C-4, Cq), 70.0 (C-3), 69.7 (C-5), 69.3 (C-2), 53.0 (CH2CH2NHBoc), 50.0 (C-6), 
48.0 (CH2N), 38.5 (CH2NHBoc), 33.8, 33.5 (CH2CO), 31.1, 31.0 (CH2CH2CH3), 28.3 
(CMe3), 24.1 (CH2CH2CO), 22.1 (CH2CH3), 13.6 (CH3); ESIMS: m/z 2558.2 [M + 2 
Na]2+, 1713.6 [M + 3 Na]3+. Anal. Calcd for C245H420N42O70: C 57.99, H 8.34, N 11.59. 
Found: C 57.72, H 8.20, N 11.24. 
Heptakis[6-(4-(2,2-bis(tert-butoxycarbonylamino)ethylaminomethyl)-1H-
1,2,3-triazol-1-yl)-6-deoxy-2,3-di-O-myristoyl]cyclomaltoheptaose (10). A solution 
of heptakis[2,3-di-O-myristoyl-6-azido-6-deoxy]cyclomaltoheptaose (3, 50 mg, 11 
μmol), 5 (34 mg, 0.1 mmol, 1.3 eq), CuI(EtO)3P (3 mg, 8  μmol, 0.1 eq) and N-
ethyldiisopropylamine (13 μL, 80 μmol, 1 eq) in acetone (5 mL) was refluxed for 6 h. 
The solvent was evaporated under reduced pressure and the residue was purified by 
column chromatography (30:1 → 9:1 CH2Cl2:MeOH) to give an amorphous solid. 
Yield:  61.3 mg (80%). [α]D = +26.2 (c 0.9, CH2Cl2); Rf = 0.51 (9:1 CH2Cl2-MeOH); 1H 
NMR ( 500 MHz, CDCl3, 333 K): δ  7.28 (s, 7 H, =CH), 5.45 (s, 7 H, H-1), 5.38 (t, 7 H, 
J2,3 = J3,4 = 9.2 Hz, H-3), 5.19 (bs, 14 H, NHBoc), 4.90 (d, 7 H, J6a,6b = 13.7 Hz, H-6a), 
4.75 (dd, 14 H, J1,2 = 3.6 Hz, H-2, H-6b), 4.53 (m, 7 H, H-5), 3.78 (2d, 14 H, 2JHa,Hb = 
15.7 Hz, CH2N), 3.55 (t, 7 H, J4,5 = 8.1 Hz, H-4), 3.18 (bq, 28 H, 3JH,H = 5.2 Hz, 
CH2NHBoc), 2.58 (bs, 28 H, CH2CH2NHBoc), 2.44-2.15 (m, 28 H, CH2CO), 1.60-1.54 
(m, 28 H, CH2CH2CO), 1.46 (s, 126 H, CMe3), 1.38-1.29 (m, 280 H, (CH2)10), 0.92 (t, 
42 H, 3JH,H = 6.5 Hz, CH3); 13C NMR (125.7 MHz, CDCl3, 313 K): δ 172.9, 171.7 (CO 
ester), 156.2 (CO carbamate), 143.6 (C-4 triazole), 125.7 (C-5 triazole), 96.6 (C-1), 79.0 
(C-4,Cq), 70.1 (C-3), 69.7 (C-5, C-2), 53.1 (CH2CH2NHBoc), 50.1 (C-6), 48.0 (CH2N), 
38.4 (CH2NHBoc), 34.0, 33.7 (CH2CO), 31.9 (CH3CH2CH2), 29.8-28,9 
(CH3CH2CH2(CH2)7), 28.5 (CMe3), 24.6 (CH2CH2CO), 22.5 (CH3CH2), 14.0 (CH3); 
ESIMS: m/z 2228.6 [M + 2 Na + H]3+, 1681.2 [M +K + 2 Na + H]4+. Anal. Calcd for 
C357H644N42O70: C 64.53, H 9.77, N 8.85. Found C 64.41, H 9.62, N 8.58. 
General Procedure for the Preparation of Unprotected Rigid Amphiphilic 
Click Clusters (11-15).  Treatment of the corresponding hepta- o tetradecacarbamate 
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(6-10, 33 μmol) with TFA-CH2Cl2 (1:1, 2 mL) at rt for 2 h, followed by evaporation of 
the solvents and freeze-drying from a diluted HCl solution, gave pure 11-15. 
Heptakis[6-(4-aminomethyl-1H-1,2,3-triazol-1-yl)-6-deoxy]-cyclomalto-
heptaose (11): Yield: 63.4 mg (99%); [α]D = +25.6 (c 1.0, H2O); 1H NMR (500 MHz, 
D2O, 323 K): δ 8.08 (s, 7 H, =CH), 5.08 (d, 7 H, J1,2 = 2.5 Hz, H-1), 4.41 (dd, 7 H, J6a,6b 
= 14.2 Hz, J5,6a = 3.0 Hz, H-6a), 4.30 (dd, 7 H, J5,6b = 6.5 Hz, H-6b), 4.20 (ddd, 7 H, J4,5 
= 9.5 Hz, H-5), 4.11, 4.09 (2 d, 14 H, 2JH,H = 14.5 Hz, CH2NH2), 3.97 (t, 7 H, J2,3 = J3,4 
= 9.5 Hz, H-3), 3.54 (dd, 7 H, H-2), 3.30 (t, 7 H, H-4); 13C NMR (125.7 MHz, D2O, 323 
K): δ 140.1 (C-4 triazole), 127.5 (C-5 triazole), 102.9 (C-1), 82.5 (C-4), 72.6 (C-3), 72.1 
(C-2), 70.2 (C-5), 50.7 (C-6), 34.3 (CH2NH2); ESIMS: m/z 879.3 [M + 2 Na + H2O]2+. 
Anal. Calcd for  C63H105Cl7N28O28: C 38.79, H 5.43, N 20.10. Found: C 38.47,  H 5.34, 
N 20.03. 
Heptakis[6-(4-(2,2-diaminoethylaminomethyl)-1H-1,2,3-triazol-1-yl)-6-
deoxy]cyclomaltoheptaose (12). Yield: 102.4 mg, (99%); [α]D = +17.0 (c 0.9, MeOH); 
1H NMR ( 500 MHz, CD3OD, 313 K): δ = 8.02 (s, 7 H, =CH), 5.16 (d, 7 H, J1,2 = 3.5 
Hz, H-1), 4.61 (dd, 7 H, J6a,6b = 15.3 Hz, J5,6a = 3.6 Hz, H-6a), 4.55 (dd, 7 H, J5,6b = 4.9 
Hz, H-6b), 4.28 (m, 7 H, H-5), 3.97 (t, 7H, J2,3 = J3,4 = 9.2 Hz, H-3), 3.83, 3.76 (2d, 14 
H, 2JH,H = 15.3 Hz, CH2N), 3.42 (dd, 7 H, H-2), 3.26 (t, 7 H, J4,5 = 9.3 Hz, H-4), 3.15 (t, 
28 H, 3JH,H = 5.7 Hz, CH2NH2), 2.79 (t, 28 H, CH2CH2NH2); 13C NMR (125.7 MHz, 
CD3OD, 313 K): δ = 143.3 (C-4 triazole), 128.0 (C-5 triazole), 103.5 (C-1), 84.2 (C-4), 
74.0 (C-3), 73.8 (C-2), 71.1 (C-5), 51.8 (CH2CH2NH2), 51.5 (C-6), 47.3 (CH2N), 38.3 
(CH2NH2); ESIMS: m/z 1149.7 [M + 2H]2+, 767.1 [M + 3H]3+. Anal. Calcd for 
C91H182Cl14N42O28: C 38.91, H 6.53, N 20.94. Found C 38.52, H 6.39, N 20.61. 
Heptakis[6-(4-aminomethyl-1H-1,2,3-triazol-1-yl)-6-deoxy-2,3-di-O-
hexanoyl]cyclomaltoheptaose (13): Yield: 106.4 mg (99%); [α]D = +31.5 (c 1.0, 
MeOH); 1H NMR (500 MHz, CD3OD, 313 K): δ 7.98 (s, 7 H, =CH), 5.49 (t, 7 H, J2,3 = 
J3,4 = 9.3 Hz, H-3), 5.46 (s, 7 H, H-1), 4.88 (d, 7 H, J6a,6b = 14.0 Hz, H-6a), 4.78 (dd, 7 
H, J1,2 = 2.1 Hz, H-2), 4.65 (s, 7 H, H-6b), 4.53 (bs, 7 H, H-5), 3.91 (s, 14 H, CH2NH2), 
3.67 (t, 7 H, J4,5 = 8.5 Hz, H-4), 2.47-2.21 (m, 28 H, CH2CO), 1.64 (m, 28 H, 
CH2CH2CO), 1.36 (m, 56 H, CH2CH3, CH2CH2CH3), 0.94 (t, 42 H, 3JH,H = 7.0 Hz, 
CH3); 13C NMR (125.7 MHz, CD3OD, 313 K): δ174.3, 173.4 ( CO ester), 145.5 (C-4 
triazole), 126.8 (C-5 triazole), 98.1 (C-1), 78.8 (C-4), 71.5 (C-5), 71.1 (C-3, C-2), 51.6 
(C-6), 36.5 (CH2NH2), 35.0, 34.9 (CH2CO), 32.5, 32.4 (CH2CH2CH3), 25.5 
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(CH2CH2CO), 23.4 (CH2CH3), 14.2 (CH3); MS (ESI): m/z 1023.9 [M + 3 H]3+, 1535.3 
[M + 2 H]2+; Anal. Calcd for C147H238N28O42: C 53.10, H 7.43, N 11.80. Found: C 
52.77, H 7.24, N 11.69 
Heptakis[6-(4-(2,2-diaminoethylaminomethyl)-1H-1,2,3-triazol-1-yl)-6-
deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (14): Yield: 136.4 mg (99%); [α]D = 
+18.5 (c 1.0, MeOH); 1H NMR (500 MHz, CD3OD, 313 K): δ 8.11 (s, 7 H, =CH), 5.60 
(t, 7 H, J2,3 = J3,4 = 9.9 Hz, H-3), 5.59 (s, 7 H, H-1), 5.15 (dd, 7 H, J6a,6b = 15.2 Hz, J5,6a 
= 2.5 Hz, H-6a), 4.58 (dd, 7 H, J5,6b = 3.0 Hz, H-6b), 4.57 (m, 14 H, J1,2 = 3.5 Hz, H-2, 
H-5), 3.91, 3.89 (2 d, 14 H, 2JHa,Hb = 15.3 Hz, CH2N), 3.54 (t, 7 H, J4,5 = 8.9 Hz, H-4), 
3.15 (t, 28 H, 3JH,H = 6.0 Hz, CH2NH2), 2.83 (t, 28 H, CH2CH2NH2), 2.49-2.17 (m, 28 
H, CH2CO), 1.73-1.58 (m, 28 H, CH2CH2CO), 1.37 (m, 56 H, CH2CH3, CH2CH2CH3), 
0.94, 0.92 (2 t, 42 H, 3JH,H = 7.1 Hz, 3JH,H = 6.9 Hz, CH3); 13C NMR (125.7 MHz, 
CD3OD, 313 K): δ175.7, 174.6 (CO ester), 144.6 (C-4 triazole), 129.7 (C-5 triazole), 
99.2 (C-1), 79.4 (C-4), 73.0 (C-2), 72.9 (C-5), 71.7 (C-3), 53.0 (CH2CH2NH2), 52.6 (C-
6), 48.3 (CH2N), 39.4 (CH2NH2), 36.3, 36.2 (CH2CO), 33.9, 33.7 (CH2CH2CH3), 26.8 
(CH2CH2CO), 24.7 (CH2CH3), 15.6 (CH3); ESIMS: m/z 1837 [M + 2 H]2+, 1225.0 [M + 
3 H]3+, 919.0 [M + 4 H]4+, 735.4 [M + 5 H]5+. Anal. Calcd for C175H322Cl14N42O42: C 
50.25, H 7.76, N 14.06. Found: C 49.98, H 7.65, N 13.79. 
Heptakis[6-(4-(2,2-diaminoethyl)aminomethyl)-1H-1,2,3-triazol-1-yl)-6-
deoxy-2,3-di-O-myristoyl]cyclomaltoheptaose (15). Yield: 178.8 mg (99%); [α]D = 
+30.7 (c 0.9, CH2Cl2); 1H NMR ( 500 MHz, CD3OD, 313 K): δ  8.12 (s, 7 H, =CH), 
5.61 (t, 7 H, J2,3 = J3,4 = 9.3 Hz, H-3), 5.60 (s, 7 H, H-1), 5.13 (d, 7 H, J6a,6b = 13.9 Hz, 
H-6a), 4.97 (d, 7 H, H-6b), 4.57 (m, 14 H, H-2, H-5), 3.90 (2d, 14 H, 2JH,H= 15.3 Hz, 
CH2N), 3.55 (t, 7 H, J4,5 = 9.2 Hz, H-4), 3.16 (t, 28 H, 3JH,H = 5.5 Hz, CH2NH2), 2.82 (t, 
28 H, CH2CH2NH2), 2.50-2.15 (m, 28 H, CH2CO), 1.80-1.55 (m, 28 H, CH2CH2CO),  
1.50-1.25 (m, 280 H, CH3(CH2)10CH2CH2CO), 0.93 (t, 42 H, 3JH,H = 6.6 Hz, CH3); 13C 
NMR (125.7 MHz, CDCl3, 313 K): δ 172.9, 171.8 (CO ester), 142.0 (C-4 triazole), 
126.9 (C-5 triazole), 96.6 (C-1), 76.7 (C-4), 70.4 (C-5, C-2), 69.1 (C-3), 50.4 
(CH2CH2NH2), 49.9 (C-6), 45.7 (CH2N), 36.7 (CH2NH2), 33.6 (CH2CO), 31.7, 29.8-
29.1, 22.3 (CH3(CH2)10CH2CH2CO), 24.6, 24.5 (CH2CH2CO), 13.0 (CH3); ESIMS: m/z 
2622.0 [M + 2 H]2+, 1748.4 [M + 3H]3+, 1311.7 [M + 4 H]4+, 1049.7 [M + 5 H]5+. Anal. 
Calcd for C287H546Cl14N42O42: C 59.91, H 9.56, N 10.22. Found C 59.58, H 9.22, N 
9.97. 
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Heptakis[6-(2-chloroacetamidoethylthio)-6-deoxy-2,3-di-O-hexanoyl]-
cyclomaltoheptaose (17): To a solution of the heptahydrochloride 16 (500 mg, 0.16 
mmol) in dry DMF (10 mL), under Ar atmosphere, DMAP (270 mg, 2.24 mmol, 2 eq) 
was added in portions and the mixture was stirred for 15 min. Chloroacetic anhydride 
(570 mg, 3.36 mmol, 3 eq) was added and the reaction was further stirred overnight at 
rt. The solvent was evaporated under reduced pressure and the residue was dissolved in 
CH2Cl2, washed with slightly acidified water (3 x 20 mL), saturated aqueous NaHCO3 
(3 x 20 mL) and water (3x 20 mL). The organic phase was dried (MgSO4), filtered and 
concentrated. The residue was purified by column chromatography (30:1 CH2Cl2-
MeOH). Yield: 325 mg (59%); Rf = 0.53 (9:1 CH2Cl2-MeOH); [α]D = +80.3 (c 1.0, 
CH2Cl2); 1H NMR (CDCl3, 500 MHz, 313 K) δ 5.35 (t, 7 H, J2,3 = J3,4 = 9.5 Hz, H-3), 
5.14 (d, 7 H. J1,2 = 4 Hz, H-1), 4.80 (dd, 7 H, H-2) 4.21 (m, 7 H, J4,5 = 9.0 Hz, J5,6a = 2.5 
Hz, J5,6b = 5.0 Hz, H-5) 4.11 (2 d, 14 H, 2JH,H = 15.0 Hz, CH2Cl), 3.82 (t, 7H, H-4), 3.55 
(m, 14 H, CH2NHCyst), 3.16 (dd, 7H, J6a,6b = 14.0 Hz, H-6a), 3.10 (dd, 7H, H-6b), 2.85 
(2dt, 14 H, 2JH,H = 13.5 Hz, 3JH,H = 6.5 Hz ,CH2SCyst), 2.43-2.17 (m, 28 H, CH2CO), 
1.70-1.57 (m, 28 H, CH2CH2CO), 1.36-1.29 (m, 56 H, CH2CH2CH3, CH2CH3), 0.92 (2 t, 
42 H, 3JH,H = 7.0 Hz, 3JH,H = 7.5 Hz,  CH3); 13C NMR (125.7 MHz, CDCl3, 313 K) δ 
173.3, 171.7 (CO ester), 166.5 (CO amide), 96.6 (C-1), 78.6 (C-4), 71.3 (C-5), 70.5(C-
2) 70.3 (C-3), 42.7 (CH2Cl), 39.4 (CH2NHCyst), 34.1, 33.8 (CH2CO, C-6), 32.9 
(CH2SCyst), 31.4, 31.3 (CH2CH2CH3), 24.3 (CH2CH2CO), 22.3 (CH2CH3), 13.8 (CH3); 
ESIMS: m/z 1175.3 [M +3 Na]3+, 1752 [M + 2 Na]2+, 3477.7 [M + Na]+. Anal. Calcd 
for C154H252Cl7N7O49S7: C 53.48, H 7.34, N 2.84, S 6.49. Found: C 53.37, H 7.21, N 
2.65, S 6.33. 
Heptakis[6-(2-azidoacetamidoethylthio)-6-deoxy-2,3-di-O-hexanoyl]-
cyclomaltoheptaose (18): To a solution of 17 (109 mg, 31 μmol) in dry DMF (10 mL), 
under Ar atmosphere, NaN3 (43 mg, 0.66 mmol, 3 eq) was added and the mixtures was 
stirred overnight.  The solvent was eliminated under vacuum and the residue was 
dissolved in CH2Cl2 (50 mL), washed with H2O (3 x 15 mL), dried (MgSO4), filtered 
and concentrated. The resulting residue was purified by column chromatography 
(50:1→ 30:1 CH2Cl2:MeOH).Yield: 93.2 mg (89%); Rf = 0.48 (9:1 CH2Cl2:MeOH). 
[α]D = +94.0 (c 1.0, CH2Cl2) ; 1H NMR (CDCl3, 300 MHz) δ 5.34 (t, 7 H, J2,3 = J3,4 = 
9.6 Hz, H-3), 5.12 (d, 7 H,  J1,2 = 3.6 Hz, H-1), 4.80 (dd, 7 H, H-2) 4.17 (m, 7 H, H-5) 
4.02 (s, 14 H, CH2N3), 3.82 (t, 7 H, J4,5 = 8.7 Hz, H-4) 3.51 (m, 14 H, CH2NHCyst), 3.10 
(m, 14 H, H-6a, H-6b), 2.82 (2 dt, 14 H, 2JH,H = 13.8 Hz, 3JH,H = 7.2 Hz , CH2SCyst), 2.44-
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2.12 (m, 28 H, CH2CO) 1.62-1.55 (m, 28 H, CH2CH2CO), 1.34-1.30 (m, 56 H, 
CH2CH2CH3, CH2CH3), 0.92 (2 t, 42 H, 3JH,H = 11.1 Hz, 3JH,H = 11.4 Hz, CH3); 13C 
NMR (75.5 MHz, CDCl3, 313 K) δ 173.7, 172.0 (CO ester), 167.7 (CO amide), 96.7 (C-
1), 78.8 (C-4), 71.5 (C-5), 70.8 (C-2), 70.5 (C-3), 52.8 (CH2N3), 39.2 (CH2NHCyst), 
34.3, 34.1 (CH2CO), 33.8 (C-6), 33.1 (CH2SCyst), 31.7, 31.6 (CH2CH2CH3), 24.7 
(CH2CH2CO), 22.7 (CH2CH3), 14.2 (CH3); ESIMS: m/z 1774.6 [M + 2 Na]2+. Anal. 
Calcd for C154H252N28O49S7: C 52.78, H 7.25, N 11.19, S 6.41. Found C 52.56, H 7.14, 
N 10.98, S 6.19. 
Heptakis[6(2-(4-(N-tert-butoxycarbonyl)aminomethyl)-1H-1,2,3-triazol-1-
yl)acetamidoethylthio)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose  (19): To a 
solution of 18 (45 mg, 13 μmol) and 4 (19 mg, 0.12 mmol, 1.3 eq)  in acetone (5 mL), 
(EtO)3P·CuI (3 mg, 9 μmol, 0.1 eq) and DIPEA (15 μL, 90 μmol, 1 eq) were added and 
the mixture was refluxed for 4 h. The solvent was evaporated under reduced pressure 
and the residue was purified by column chromatography (20:1 → 9:1 CH2Cl2:MeOH). 
Yield: 53 mg (89%); Rf = 0.4 (9:1 CH2Cl2:MeOH); [α]D = +67.6 (c 1.0, CH2Cl2);  1H 
NMR (CD3OD, 500 MHz, 323 K) δ 7.90 (s, 7 H, =CH), 5.32 (t, 7 H, J2,3 = J3,4 = 8.5 Hz, 
H-3), 5.15 (d, 7 H, J1,2 = 3.6 Hz, H-1), 5.13 (s, 14 H, CH2CONH), 4.87 (dd, 7 H, H-2), 
4.34 (s, 14 H, CH2NHBoc), 4.28 (m, 7 H, H-5), 3.84 (t, 7 H, J4,5 = 8.0 Hz, H-4), 3.54 
(m, 14 H, CH2NHCyst), 3.40 (m, 7 H, H-6a), 3.08 (dd, 7 H, J6a,6b = 13.9 Hz, J5,6b = 7.0 
Hz, H-6b), 2.88 (m, 14 H, CH2SCyst), 2.50-2.22 (m, 28 H, CH2CO), 1.70-1.57 (m, 28 H, 
CH2CH2CO), 1.42 (s, 63 H, CMe3), 1.40-1.30 (m, 56 H, CH2CH2CH3, CH2CH3), 0.96, 
0.95 (2 t, 42 H, 3JH,H = 7.0 Hz, CH3);  13C NMR (125.7 MHz, CD3OD): δ 174.5, 173.3 
(CO ester), 167.9  (CO amide), 158.1 (CO carbamate), 147.4 (C-4 triazole), 125.7 (C-5 
triazole), 98.3 (C-1), 80.6 (C-4, Cq), 72.9 (C-5), 72.1 (C-3), 71.6 (C-2), 53.4 
(CH2CONH), 40.7 (CH2NHCyst), 37.0 (CH2NHBoc) 35.1 (CH2CO), 32.6, 32.5 
(CH2CH2CH3, CH2SCyst, C-6), 28.9 (CMe3), 25.5 (CH2CH2CO), 23.4 (CH2CH3), 14.4 
(CH3); MS ESI: (m/z) 4606.9 [M + Na]+, 2317.9 [M + 2Na]2+, 1552.2 [M+ 3 Na]3+. 
Anal. Calcd for C210H343N35O63S7: C 54.94, H 7.53 N 10.68, S 4.89. Found C 54.72, H 
7.38 N 10.47, S 4.60.  
Heptakis[6-(2-(4-(2,2-bis(tert-butoxycarbonylamino)ethylaminomethyl)-1H-
1,2,3-triazol-1-yl)acetamidoethylthio-6-deoxy-2,3-di-O-
hexanoyl]cyclomaltoheptaose (20): To a solution of 18 (48 mg, 14 μmol) and  5 (44 
mg, 0.13 mmol, 1.3 eq.) in acetone (5 mL), CuI·(EtO)3P (4 mg, 10 μmol, 0.1 eq.) and 
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DIPEA (17 μL, 0.1 mmol, 1 eq.) were added and the reaction mixture was refluxed for 
3 h. Solvent was eliminated under vacuum and the residue was purified by column 
chromatography (30:1 → 9:1 CH2Cl2-MeOH) to give 20. Yield: 65 mg (79%); Rf = 0.36 
(9:1 CH2Cl2:MeOH); [α]D = +51.5 (c 1.0, CH2Cl2); 1H NMR (500 MHz, CDCl3, 313 
K): δ 7.81 (s, 7 H, =CH), 5.34 (s, 14 H, NHBoc) 5.26 (t, 7 H, J2,3 = J3,4 = 7.9 Hz, H-3), 
5.10 (m, 21 H, CH2CONH, H-1), 4.76 (bd, 7 H, H-2), 4.14 (bs, 7 H, H-5), 3.81 (bs, 14 
H, CH2N), 3.72 (bt, 7H, J4,5 = 6.95 Hz, H-4), 3.44 (m, 14 H, CH2NHCyst), 3.18 (bs, 14 
H, CH2NHBoc), 2.98 (bs, 7 H, H-6a), 2.80 (bs, 14 H, CH2SCyst), 2.73 (bs, 7 H, H-6b), 
2.58 (s, 14 H, CH2CH2NHBoc), 2.42-2.10 (m, 28 H, CH2CO), 1.65-1.50 (m, 28 H, 
CH2CH2CO), 1.42 (s, 126 H, CMe3), 1.38-1.20 (m, 56 H, CH2CH2CH3, CH2CH3), 0.95-
0.84 (2 t, 42 H, 3JH,H = 7.3 Hz, 3JH,H = 7.0 Hz, CH3); 13C NMR (125.7 MHz, CDCl3, 313 
K): δ 173.4, 171.6 (CO ester), 166.0 (CO amide), 156.3 (CO carbamate) 144.1 (C-4 
triazole), 125.1 (C-5 triazole), 96.6 (C-1), 79.1 (C-4, Cq), 71.4 (C-5), 70.4 (C-3, C-2), 
53.3 (CH2CONH), 52.4 (CH2CH2NHBoc), 48.3 (CH2N), 39.4 (CH2NHCyst), 38.4 
(CH2NHBoc) 34.0, 33.8 (CH2CO),  32.9 (C-6, CH2SCyst), 31.3, 31.2 (CH2CH2CH3), 
28.5 (CMe3), 24.3 (CH2CH2CO), 22.3 (CH2CH3), 13.8 (CH3); ESIMS: m/z 2969.7 [M + 
2 Na]2+, 2959.0 [M+ H + Na]2+. Anal. Calcd for C273H469N49O77S7: C 55.6, H 8.02, N 
11.64, S 3.81. Found C 55.47, H 7.89, N 11.50, S 3.65. 
General Procedure for the Preparation of Unprotected Flexible 
Amphiphilic Click Clusters (21, 22).  Treatment of the corresponding hepta- or 
tetradecacarbamate (19 or 20, 19 μmol) with TFA-CH2Cl2 (1:1, 2 mL) at rt for 2 h, 
followed by evaporation of the solvents and freeze-drying from a diluted HCl solution, 
gave pure 21-22. 
Heptakis[6(2-(4-aminomethyl)-1H-1,2,3-triazol-1-yl)methylcarbamoyl)-
ethylthio)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (21): Yield: 72 mg (91%); 
[α]D = +22.1 (c 0.8, MeOH); 1H NMR (500 MHz, CD3OD, 323 K): δ 8.21 (s, 7 H, 
=CH), 5.34 (t, 7 H, J2,3 = J3,4 = 7.9 Hz, H-3), 5.26 (s, 14 H, CH2CONH), 5.16 (d, 7 H, 
J1,2 = 3.2 Hz, H-1), 4.85 (dd, 7 H, H-2), 4.33 (s, 14 H, CH2NH2), 4.29 (bs, 7 H, H-5), 
3.87 (t, 7 H, J4,5 = 7.9 Hz, H-4), 3.54 (m, 14 H, CH2NHCyst), 3.42 (bd, 7 H, J6a,6b = 11.4 
Hz, H-6a), 3.12 (dd, 7 H, J5,6b = 4.3 Hz, H-6b), 2.91 (m, 14 H, CH2SCyst), 2.50-2.20 (m, 
28 H, CH2CO), 1.65 (m, 28 H, CH2CH2CO), 1.45-1.30 (m, 56 H, CH2CH2CH3, 
CH2CH3), 1.00-0.92 (2 t, 42 H, 3JH,H = 7.3 Hz, 3JH,H = 6.9 Hz, CH3); 13C NMR (100.3 
MHz, CD3OD, 313 K): δ 173.3, 171.9 (CO ester), 166.3 (CO amide), 139.7 (C-4 
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triazole), 126.0 (C-5 triazole), 96.8 (C-1), 79.2 (C-4), 71.2 (C-5), 70.4 (C-3), 70.1 (C-2), 
51.8 (CH2CONH), 39.1 (CH2NHCyst), 34.9 (CH2NH2), 33.6 (CH2CO, CH2SCyst, C-6), 
31.5, 31.1 (CH2CH2CH3), 24.1 (CH2CH2CO), 22.0 (CH2CH3), 13.0, 12.8 (CH3). 
ESIMS: m/z 1976.6 [M + 2 Na]2+, 1317.8 [M + 3 Na]3+, 988.1 [M + 2 H + 2 Na]4+. 
Anal. Calcd. for C175H294N35O49Cl7S7: C 50.71, H 7.15 N 11.83, S 5.42. Found C 50.35, 
H 6.89 N 11.56, S 5.11. 
Heptakis[6(2-(4-(2,2-diaminoethylaminomethyl)-1H-1,2,3-triazol-1-
yl)acetamidoethylthio)-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (22): Yield: 
81.0 mg (91%). [α]D = +39.6 (c 1.0 in MeOH); 1H NMR (500 MHz, CD3OD, 313 K): δ 
8.05 (s, 7 H, =CH), 5.36 (t, 7 H, J2,3 = J3,4 = 8.7 Hz, H-3) 5.21 (s, 14 H, CH2CONH), 
5.17 (d, 7 H, J1,2 = 3.5 Hz, H-1), 4.83 (dd, 7 H, H-2), 4.21 (bs, 7 H, H-5), 3.90 (bs, 21 H, 
CH2N, H-4), 3.52 (m, 14 H, CH2NHCyst), 3.15 (t, 14 H, CH2NH2, 3JH,H = 5.5 Hz), 3.11 
(m, 7 H, H-6a), 2.88 (m, 21 H, CH2SCyst, H-6b), 2.84 (t, 7 H, CH2CH2NH2), 2.50-2.22 
(m, 28 H, CH2CO), 1.73-1.58 (m, 28 H, CH2CH2CO), 1.43-1.30 (m, 56 H, CH2CH3), 
0.99-0.91 (2 t, 42 H, 3JH,H = 6.9 Hz, 3JH,H = 5.8 Hz, CH3); 13C NMR (125.7 MHz, 
CD3OD, 313 K): δ 176.0, 174.7 (CO ester), 169.2 (CO amide), 145.4 (C-4 triazole), 
128.5 (C-5 triazole), 99.5 (C-1), 81.8 (C-4), 74.5 (C-5), 73.0 (C-3, C-2), 54.4 
(CH2CONH), 53.4 (CH2CH2NH2), 49.1 (CH2N), 42.0 (CH2NHCyst), 39.6 (CH2NH2) 
36.4, 36.3 (CH2CO), 33.8, 33.7 (CH2CH2CH3), 32.0 (C-6, CH2SCyst) 26.8 (CH2CH2CO), 
24.7 (CH2CH3), 15.7, 15.6 (CH3). Anal. Calcd. for C203H371Cl14N49O49S7: C 48.73, H 
7.47, N 13.72, S 4.49. Found C 48.49, H 7.33, N 13.54, S 4.14. 
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Figure S1. 1H and 13C  NMR spectra (500 MHz, 125.7 MHz, CDCl3) of 2. 
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Figure S2. 1H and 13C  NMR spectra (500 MHz, 125.7 MHz, CDCl3) of 3. 
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Figure S3. 1H and 13C  NMR spectra (500 MHz, 125.7 MHz, CD3OD, 323 K) of 6. 
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Figure S4. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CD3OD, 313 K) of 7. 
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Figure S5. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CDCl3, 313 K) of 8. 
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Figure S6. 1H and 13C NMR spectra (400 MHz, 100.6 MHz,, CDCl3, 323 K) of 
9. 
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Figure S7. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CD3OD, 313 K) of 10. 
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Figure S8. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, D2O) of 11. 
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Figure S9. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CD3OD, 313 K) of 12. 
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Figure S10.  1H and 13C NMR spectra (500 MHz, 125.7 MHz, CD3OD, 313 K) of 13. 
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Figure S11. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CD3OD, 313 K) 
of 14. 
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Figure S12. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CD3OD, 313 K) 
of 15. 
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Figure S13. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CD3OD) of 16. 
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Figure S14. 1H and 1 D TOCSY NMR spectra (500 MHz, CDCl3,, 313 K) of 17. 
 30
COEster
CH N2 3
C-6
CH S2 Cyst
CH NH2
COamide
C-1
C-4
C-5
C-2 C-3
727374757677787980818283848586878889909192939495969720253035404550 ppm
H-2
H-1
H-4H-3
H-5
H-6a,b
CH N2 Cyst
CH N2 3
3.23.43.63.84.04.24.44.64.85.05.25.4 ppm
7
O
ORO
RO
N3S N
H
O
R = -C(=O)C5H11
CH S2 Cyst
1.01.52.02.53.03.54.04.55.05.5 ppm
2030405060708090100110120130140150160170 ppm  
 
Figure S15. 1H and 13C NMR spectra (500 MHz, 75.5 MHz, CDCl3) of 18. 
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Figure S16. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CD3OD, 323 K) 
of 19. 
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Figure S17. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CDCl3, 313 K) of 
20. 
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Figure S18. 1H and 13C NMR spectra (500 MHz, 100.3 MHz, CD3OD, 323 K) of 21. 
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Figure S19. 1H and 13C NMR spectra (500 MHz, 125.7 MHz, CD3OD, 313 K) 
of 22. 
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